Abbvie Inc

NYSE: ABBV
$200.80
+$0.29 (+0.1%)
Real Time Data Delayed 15 Min.

ABBV Articles

The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking for.
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7 in Chicago.
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates for generic...
AbbVie reported its first-quarter financial results and guidance before the markets opened on Thursday.
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical...
These four Jefferies Franchise Picks are rated Buy and pay the highest dividends. They make good sense for investors now.
The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Now all investor eyes turn to first-quarter earnings results. With interest rates still very low, investors looking to add capital should still focus on top dividend-paying stocks.
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes...
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.